Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

Urology

Volumn 63, Issue 5, 2004, Pages 934-939

  Tiffany, N M ^a   Wersinger, E M ^a   Garzotto, M ^a   Beer, T M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ASPARTATE AMINOTRANSFERASE; CREATININE; IMATINIB; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE PAIN; BONE TURNOVER; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MALE; NAUSEA; PAIN ASSESSMENT; PETECHIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PAIN; PIPERAZINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIMIDINES; TREATMENT FAILURE;

EID: 2342565080     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.12.022     Document Type: Article

References (31)

1. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative end points. J Clin Oncol. 14:1996;1756-1764
2. Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 31:1994;33-40
3. Clarke N.W., McClure J., George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 68:1991;74-80
4. Garnero P., Buchs N., Zekri J., et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 82:2000;858-864
5. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 94:2002;1458-1468
6. Pelger R.C., Hamdy N.A., Zwinderman A.H., et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 22:1998;403-408
7. Vinholes J.J., Purohit O.P., Abbey M.E., et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 8:1997;1243-1250
8. Lee M.V., Fong E.M., Singer F.R., et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61:2001;2602-2608
9. Brown L.G., Vessella R.L., Corey E. Effects of zoledronic acid on prostate cancer cells. J Bone Miner Res. 15:2000;S446
10. Corey E., Brown L.G., Quinn J.E., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 9:2003;295-306
11. Oades G.M., Senaratne S.G., Clarke I.A., et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol. 170:2003;246-252
12. Boisseir S., Magnetto S., Delmas P.D., et al. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independent of apoptosis induction. Bone. 32:1998;S558
13. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2000;2949-2954
14. Pirtskhalaishvili G., Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 44:2000;77-87
15. Sitaras N.M., Sariban E., Bravo M., et al. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res. 48:1988;1930-1935
16. Ko Y.J., Small E.J., Kabbinavar F., et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 7:2001;800-805
17. Shawver L.K., Schwartz D.P., Mann E., et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoroethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res. 3:1997;1167-1177
18. Uehara H., Kim S.J., Karashima T., et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 95:2003;458-470
19. Melzack R. The McGill Pain Questionnaire major properties and scoring methods. Pain. 1:1975;277-299
20. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216
21. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30 a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:1993;365-376
22. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 17:1999;3461-3467
23. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 61:1988;195-202
24. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037
25. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566
26. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145
27. Cortes J., Giles F., O'Brien S., et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 102:2003;83-86
28. Benjamin R.S., Rankin C., Fletcher C., et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST Intergroup S0033 early results. Proc Am Soc Oncol. 22:2003;814
29. Verwij J., Casali P.G., Zalcberg J., et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST) interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Oncol. 22:2003;814
30. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 38:(suppl 5):2002;S83-S87
31. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med. 349:2003;366-381